NCT03487133View on ClinicalTrials.gov

Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Relapsed and/or Refractory Cutaneous T-cell Lymphoma
Interventions
DRUG

bortezomib/dexamethasone

"Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"

Trial Locations (1)

676

Samsung medical center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03487133 - Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma | Biotech Hunter | Biotech Hunter